通过体内电穿孔递送的基于DNA的候选HIV疫苗可在健康志愿者中诱导针对HIV gp120的α4β7结合V2环的CD4反应。
A DNA-based candidate HIV vaccine delivered via in vivo electroporation induces CD4 responses toward the α4β7-binding V2 loop of HIV gp120 in healthy volunteers.
作者信息
Kopycinski Jakub, Cheeseman Hannah, Ashraf Ambreen, Gill Dilbinder, Hayes Peter, Hannaman Drew, Gilmour Jill, Cox Josephine H, Vasan Sandhya
机构信息
IAVI Human Immunology Laboratory, Imperial College, London, United Kingdom.
出版信息
Clin Vaccine Immunol. 2012 Sep;19(9):1557-9. doi: 10.1128/CVI.00327-12. Epub 2012 Jul 25.
Abstract
Administration of a clade C/B' candidate HIV-1 DNA vaccine, ADVAX, by in vivo electroporation (EP) was safe and more immunogenic than intramuscular administration without EP. The breadth and specificity of T-cell responses to full-length Env were mapped. Responses to multiple Env regions were induced, with most focusing on V3/C4 and V2 regions, including the α4β7 integrin-binding domain. The breadth of responses induced by this DNA vaccine regimen was comparable to that of viral-vectored vaccine regimens.
摘要
通过体内电穿孔（EP）接种C/B'亚型候选HIV-1 DNA疫苗ADVAX是安全的，且比无EP的肌肉注射免疫原性更强。对全长Env的T细胞反应的广度和特异性进行了图谱分析。诱导了对多个Env区域的反应，大多数集中在V3/C4和V2区域，包括α4β7整合素结合域。这种DNA疫苗方案诱导的反应广度与病毒载体疫苗方案相当。
相似文献
1
A DNA-based candidate HIV vaccine delivered via in vivo electroporation induces CD4 responses toward the α4β7-binding V2 loop of HIV gp120 in healthy volunteers.
Clin Vaccine Immunol. 2012 Sep;19(9):1557-9. doi: 10.1128/CVI.00327-12. Epub 2012 Jul 25.
2
Immunogenicity, safety, biodistribution and persistence of ADVAX, a prophylactic DNA vaccine for HIV-1, delivered by in vivo electroporation.
Vaccine. 2011 Jan 17;29(4):795-803. doi: 10.1016/j.vaccine.2010.11.011. Epub 2010 Nov 19.
3
In vivo electroporation in DNA-VLP prime-boost preferentially enhances HIV-1 envelope-specific IgG2a, neutralizing antibody and CD8 T cell responses.
Vaccine. 2017 Apr 11;35(16):2042-2051. doi: 10.1016/j.vaccine.2017.03.006. Epub 2017 Mar 17.
4
In vivo electroporation enhances the immunogenicity of an HIV-1 DNA vaccine candidate in healthy volunteers.
PLoS One. 2011;6(5):e19252. doi: 10.1371/journal.pone.0019252. Epub 2011 May 16.
5
HIV-DNA Given with or without Intradermal Electroporation Is Safe and Highly Immunogenic in Healthy Swedish HIV-1 DNA/MVA Vaccinees: A Phase I Randomized Trial.
PLoS One. 2015 Jun 29;10(6):e0131748. doi: 10.1371/journal.pone.0131748. eCollection 2015.
6
Combined Skin and Muscle DNA Priming Provides Enhanced Humoral Responses to a Human Immunodeficency Virus Type 1 Clade C Envelope Vaccine.
Hum Gene Ther. 2018 Sep;29(9):1011-1028. doi: 10.1089/hum.2018.075.
7
Identification of New Regions in HIV-1 gp120 Variable 2 and 3 Loops that Bind to α4β7 Integrin Receptor.
PLoS One. 2015 Dec 1;10(12):e0143895. doi: 10.1371/journal.pone.0143895. eCollection 2015.
8
HIV-1 gp120 and Modified Vaccinia Virus Ankara (MVA) gp140 Boost Immunogens Increase Immunogenicity of a DNA/MVA HIV-1 Vaccine.
J Virol. 2017 Nov 30;91(24). doi: 10.1128/JVI.01077-17. Print 2017 Dec 15.
9
Potent CD4+ T cell responses elicited by a bicistronic HIV-1 DNA vaccine expressing gp120 and GM-CSF.
J Immunol. 2002 Jan 15;168(2):562-8. doi: 10.4049/jimmunol.168.2.562.
10
Induction of Identical IgG HIV-1 Envelope Epitope Recognition Patterns After Initial HIVIS-DNA/MVA-CMDR Immunization and a Late MVA-CMDR Boost.
Front Immunol. 2020 Apr 28;11:719. doi: 10.3389/fimmu.2020.00719. eCollection 2020.
引用本文的文献
1
Development and Evaluation of an Ebola Virus Glycoprotein Mucin-Like Domain Replacement System as a New Dendritic Cell-Targeting Vaccine Approach against HIV-1.
J Virol. 2021 Jul 12;95(15):e0236820. doi: 10.1128/JVI.02368-20.
2
Immunogenicity evaluation of the HIV-1 Tat containing polyepitope DNA vaccine adjuvanted with CpG-ODNs in mice.
Iran J Basic Med Sci. 2021 Mar;24(3):377-382. doi: 10.22038/ijbms.2021.52890.11923.
3
DNA Vaccination by Electroporation Amplifies Broadly Cross-Restricted Public TCR Clonotypes Shared with HIV Controllers.
J Immunol. 2017 Nov 15;199(10):3437-3452. doi: 10.4049/jimmunol.1700953. Epub 2017 Oct 9.
4
HIV Env conserved element DNA vaccine alters immunodominance in macaques.
Hum Vaccin Immunother. 2017 Dec 2;13(12):2859-2871. doi: 10.1080/21645515.2017.1339852. Epub 2017 Jul 5.
5
An Approach for a Synthetic CTL Vaccine Design against Zika Flavivirus Using Class I and Class II Epitopes Identified by Computer Modeling.
Front Immunol. 2017 Jun 9;8:640. doi: 10.3389/fimmu.2017.00640. eCollection 2017.
6
A phase 1, randomized, controlled dose-escalation study of EP-1300 polyepitope DNA vaccine against Plasmodium falciparum malaria administered via electroporation.
Vaccine. 2016 Nov 4;34(46):5571-5578. doi: 10.1016/j.vaccine.2016.09.041. Epub 2016 Sep 30.
7
HIV DNA Vaccine: Stepwise Improvements Make a Difference.
Vaccines (Basel). 2014 May 14;2(2):354-79. doi: 10.3390/vaccines2020354.
8
Elucidating the Kinetics of Expression and Immune Cell Infiltration Resulting from Plasmid Gene Delivery Enhanced by Surface Dermal Electroporation.
Vaccines (Basel). 2013 Aug 28;1(3):384-97. doi: 10.3390/vaccines1030384.
9
Enhanced Delivery and Potency of Self-Amplifying mRNA Vaccines by Electroporation in Situ.
Vaccines (Basel). 2013 Aug 22;1(3):367-83. doi: 10.3390/vaccines1030367.
10
Skin Transfection Patterns and Expression Kinetics of Electroporation-Enhanced Plasmid Delivery Using the CELLECTRA-3P, a Portable Next-Generation Dermal Electroporation Device.
Hum Gene Ther Methods. 2015 Aug;26(4):134-46. doi: 10.1089/hgtb.2015.020.
本文引用的文献
1
The Thai phase III trial (RV144) vaccine regimen induces T cell responses that preferentially target epitopes within the V2 region of HIV-1 envelope.
J Immunol. 2012 May 15;188(10):5166-76. doi: 10.4049/jimmunol.1102756. Epub 2012 Apr 23.
2
Immune-correlates analysis of an HIV-1 vaccine efficacy trial.
N Engl J Med. 2012 Apr 5;366(14):1275-86. doi: 10.1056/NEJMoa1113425.
3
Enhanced control of pathogenic Simian immunodeficiency virus SIVmac239 replication in macaques immunized with an interleukin-12 plasmid and a DNA prime-viral vector boost vaccine regimen.
J Virol. 2011 Sep;85(18):9578-87. doi: 10.1128/JVI.05060-11. Epub 2011 Jul 6.
4
Mapping HIV-1 vaccine induced T-cell responses: bias towards less-conserved regions and potential impact on vaccine efficacy in the Step study.
PLoS One. 2011;6(6):e20479. doi: 10.1371/journal.pone.0020479. Epub 2011 Jun 10.
5
In vivo electroporation enhances the immunogenicity of an HIV-1 DNA vaccine candidate in healthy volunteers.
PLoS One. 2011;6(5):e19252. doi: 10.1371/journal.pone.0019252. Epub 2011 May 16.
6
Electroporation delivery of DNA vaccines: prospects for success.
Curr Opin Immunol. 2011 Jun;23(3):421-9. doi: 10.1016/j.coi.2011.03.008. Epub 2011 Apr 27.
7
Equivalence of ELISpot assays demonstrated between major HIV network laboratories.
PLoS One. 2010 Dec 14;5(12):e14330. doi: 10.1371/journal.pone.0014330.
8
Immunogenicity, safety, biodistribution and persistence of ADVAX, a prophylactic DNA vaccine for HIV-1, delivered by in vivo electroporation.
Vaccine. 2011 Jan 17;29(4):795-803. doi: 10.1016/j.vaccine.2010.11.011. Epub 2010 Nov 19.
9
Increasing CTL targeting of conserved sequences during early HIV-1 infection is correlated to decreasing viremia.
AIDS Res Hum Retroviruses. 2011 Apr;27(4):391-8. doi: 10.1089/aid.2010.0183. Epub 2010 Nov 18.
10
Mutation at a single position in the V2 domain of the HIV-1 envelope protein confers neutralization sensitivity to a highly neutralization-resistant virus.
J Virol. 2010 Nov;84(21):11200-9. doi: 10.1128/JVI.00790-10. Epub 2010 Aug 11.
Zotero 插件